CAR-macrophage: A new immunotherapy candidate against solid tumors
CAR-macrophage: A new immunotherapy candidate against solid tumors
复制标题
DOI：
10.1016/j.biopha.2021.111605
复制
发表时间：
2021-04-23
影响因子：
7.5
通讯作者：
Tu, Jiajie
中科院分区：
文献类型：
--
作者：
Chen, Yizhao;Yu, Zhiying;Tu, Jiajie
嵌合抗原受体(CAR)-T细胞治疗已被证明是治疗血液系统肿瘤的有效方法，但对实体肿瘤的治疗仍缺乏有效性。在肿瘤微环境中，巨噬细胞是浸润率最高的先天免疫细胞。肿瘤相关巨噬细胞(TAMs)刺激血管生成，增加肿瘤侵袭，并介导免疫抑制。由于巨噬细胞可以渗入实体肿瘤组织，并与肿瘤微环境中几乎所有的细胞成分(包括肿瘤细胞、免疫细胞如T细胞、NK细胞、树突状细胞和其他常驻的非免疫细胞)相互作用，研究人员正在尝试使用CAR修饰的巨噬细胞(CAR-M)来治疗实体肿瘤。本文综述了以CAR-M为基础的肿瘤治疗的最新报道，并总结了它们的缺点和应用前景。
Chimeric antigen receptor (CAR)-T cell therapy has been shown to be an effective treatment for hematological tumors, but the treatment of solid tumors still lacks effectiveness. In the tumor microenvironment, macrophages are the innate immune cells with the highest infiltration rate. Tumor-associated macrophages (TAMs) stimulate angiogenesis, increase tumor invasion, and mediate immunosuppression. Because macrophages can infiltrate solid tumor tissue and interact with almost all cellular components in the tumor microenvironment (including tumor cells, immune cells such as T-cells, NK cells, DCs, and other resident non-immune cells), researchers are trying to use macrophages modified with CAR (CAR-M) against solid tumors. This review describes recent reports of CAR-M-based tumor treatments and summarizes their shortcomings and future applications.